|Bid||37.70 x 1000|
|Ask||42.75 x 1200|
|Day's Range||41.67 - 42.35|
|52 Week Range||10.05 - 45.85|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
This marijuana stock is sitting on nearly a half-billion dollars in cash and cash equivalents.
The Emeryville, California-based company said it had a loss of 87 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
On April 2, 2018, Senseonics (SENS) stock opened at $3. It grew ~24% over the week to close at $3.70 on April 6. Its 52-week low was $1.26 on May 23, 2017.
From yesterday's research, analysts parsed 49 10-K filings and collected 6,142 data points. In total, they made 1,001 forensic accounting adjustments with a dollar value of $99 billion. The Robo-Analyst found an unusual item yesterday in Zogenix’s (ZGNX) 10-K.
On a per-share basis, the Emeryville, California-based company said it had a loss of $1.17. Losses, adjusted for one-time gains and costs, came to $1.14 per share. The results missed Wall Street expectations. ...
Zogenix (ZGNX) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
It’s earnings season, and a steady stream of financial figures are separating the flawed from the flourishing in the pharmaceutical sector. The Ratings Leerink reiterated Outperform ratings on the following ...
It’s no secret that hedge funds have been underperforming the market by quite a wide margin in the last couple of years. However, in the industry that encompasses hundred of hedge funds and has gathered over $3.0 trillion in assets under management, there still are many players that posted great returns. This is particularly the […]
Marijuana can reduce seizures in epilepsy patients, but another drug in clinical studies may work even better.
The stock market closed with small gains Thursday, another day of indecisive action on Wall Street.
Marinus Pharmaceuticals (MRNS) has initiated a phase two study to test the feasibility of ganaxalone in patients suffering from refractory status epilepticus (or RSE). Data from this study is expected ...
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Zogenix, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
Shares of Zogenix, Inc. (NASDAQ: ZGNX ) — a biopharma company,developing treatments for patients with rare central nervous system conditions with limited or no treatment options — could be in for further ...